Akèy › Kansè Metastatik › Kalifòni › Mountain View
Etid klinik pou Kansè Metastatik nan Mountain View, CA
25 etid pou Kansè Metastatik ap chèche patisipan nan sit nan ak bò kote Mountain View (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
Ap rekriteFaz 2
- Stanford Cancer Institute Palo Alto, Palo Alto · 5 mi lwen
- VA Palo Alto Health Care System, Palo Alto · 5 mi lwen
Study of Orellanine in Metastatic Clear-Cell or Papillary Renal Cell Carcinoma
Ap rekriteFaz 1/2
- Stanford, Palo Alto · 5 mi lwen
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
Ap rekriteFaz 2/3
- Stanford Cancer Center, Palo Alto · 5 mi lwen
Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
Ap rekriteFaz 3
- Palo Alto Medical Foundation - Palo Alto Center, Palo Alto · 5 mi lwen
A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)
Ap rekriteFaz 1/2
- Stanford Medicine, Palo Alto · 5 mi lwen
Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations
Ap rekriteFaz 1
- Stanford Cancer Institute, Stanford · 5 mi lwen
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
Ap rekriteFaz 1
- Stanford University Medical Center, Stanford · 5 mi lwen
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
Ap rekriteFaz 3
- Stanford Women's Cancer Center, Palo Alto · 5 mi lwen
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Ap rekriteFaz 3
- Stanford Cancer Center, Palo Alto · 5 mi lwen
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Ap rekriteFaz 1/2
- Stanford Cancer Institute, Stanford · 5 mi lwen
Trial Comparing LATTICE Radiotherapy vs Moderately Dose-escalated Palliative Radiation for Patients With Metastases.
Ap rekriteFaz 2
- Stanford University, Palo Alto · 5 mi lwen
A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer
Ap rekriteFaz 3
- Research Site, Palo Alto · 5 mi lwen
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer
Ap rekriteFaz 1/2
- Stanford Cancer Institute (SCI), Stanford · 5 mi lwen
FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
Ap rekriteFaz 1
- Stanford Medicine Cancer Center, Stanford · 5 mi lwen
FOG-001 in Locally Advanced or Metastatic Solid Tumors
Ap rekriteFaz 1/2
- Stanford Cancer Institute, Stanford University, Palo Alto · 5 mi lwen
Comparing SingLe- Vs Multi-Fraction Spine STereotActic Radiosurgery in Spinal Metastases
Ap rekriteFaz 3
- Stanford University School of Medicine, Palo Alto · 5 mi lwen
A Study of LY4175408 in Participants With Advanced Cancer
Ap rekriteFaz 1
- Stanford Medicine Cancer Center, Stanford · 5 mi lwen
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
Ap rekriteFaz 1/2
- Stanford Cancer Institute, Stanford · 5 mi lwen
Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma
Ap rekriteFaz 2/3
- Stanford Health Care - Skin Cancer Program, Stanford · 5 mi lwen
A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
Ap rekriteFaz 2/3
- Stanford Cancer Institute, Palo Alto · 5 mi lwen
Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
Ap rekriteFaz 1
- Stanford Cancer Institute, Stanford · 5 mi lwen
A Study of NVL-330 in Patients With Advanced or Metastatic HER2-altered NSCLC (HEROEX-1)
Ap rekriteFaz 1
- Stanford Cancer Institute, Stanford · 5 mi lwen
Intra-procedural Spectral CT for Image-guided Embolization and Ablation in Interventional Oncology
Ap rekriteEtid obsèvasyon
- VA Palo Alto Healthcare System, Palo Alto · 5 mi lwen
Evaluation of RBS2418 in Subjects With Advanced, Metastatic Solid Tumors
Ap rekriteFaz 1
- Stanford Cancer Institute, Palo Alto · 5 mi lwen
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Ap rekriteEtid obsèvasyon
- Massive Bio SYNERGY-AI site, Stanford · 5 mi lwen
Etid Kansè Metastatik nan lòt vil
- Houston, TX104 etid
- New York City, NY93 etid
- Nashville, TN70 etid
- Boston, MA63 etid
- Los Angeles, CA57 etid
- St. Louis, MO54 etid
- Arlington, VA53 etid
- Philadelphia, PA46 etid
- Chicago, IL45 etid
- San Antonio, TX44 etid
- Washington, DC43 etid
- Dallas, TX42 etid
Lòt etid nan Mountain View
- Kansè (tout kalite)40 etid
- Kansè nan tete26 etid
- Kansè Poumon ki pa ti selil21 etid
- Leksemi mieloïd egi19 etid
- Kansè ovè19 etid
- Twoub Spektòm Otis17 etid
- Kansè poumon17 etid
- Kansè pwostat15 etid
- Ensifizyans kadyak15 etid
- Otis13 etid
- Leksemi limfoblastik egi13 etid
- Kansè kolorektal13 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.